Development of resistance results from mutations in the viral genome, and the presence of selective drug pressure leads to the emergence of a resistant virus population. The aim of this study was to analyze the impact of genetic variability on the genetic barrier to drug resistance to DAAs.The genetic barrier was quantified based on the number and type of nucleotide mutations required to impart resistance, considering full-length HCV NS3, NS5A and NS5B regions segregated by genotype into subtypes 1a, 1b, 2a, 2b and 3a. This study analyzeds 789 NS3 sequences, 708 sequences and 536 NS5B sequences deposited in the European Hepatitis C Virus Database, in the following resistance-associated positions: NS3: F43/I/L/S/V, Q80K/R, R155K/G, A156G/S/T...
Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide a...
BACKGROUND: Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed wheth...
The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients w...
Background & Aims: Development of resistance results from mutations in the viral genome, and the pre...
Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed the NS5B polymera...
Direct-acting antiviral (DAA) agents target HCV proteins; some of these have already been approved f...
Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific ...
Because of the high variability of Hepatitis C virus (HCV), it might be important to characterize in...
Treatment with pan-genotypic direct-acting antivirals, targeting different viral proteins, is the be...
Background In order to clear HCV in chronically infected patients, treatment with combinations of pa...
Hepatitis C virus (HCV) inhibitors include direct-acting antivirals (DAAs) such as NS3 serine protea...
Different HCV subtypes may naturally harbor different resistance selection to anti-NS5a inhibitors. ...
Background: Direct-acting antivirals (DAAs) are predicted to transform hepatitis C therapy, yet litt...
Several new direct-acting antiviral (DAA) drugs are in development for chronic hepatitis C viral (HC...
Treatment with pan-genotypic direct-acting antivirals, targeting different viral proteins, is the be...
Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide a...
BACKGROUND: Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed wheth...
The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients w...
Background & Aims: Development of resistance results from mutations in the viral genome, and the pre...
Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed the NS5B polymera...
Direct-acting antiviral (DAA) agents target HCV proteins; some of these have already been approved f...
Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific ...
Because of the high variability of Hepatitis C virus (HCV), it might be important to characterize in...
Treatment with pan-genotypic direct-acting antivirals, targeting different viral proteins, is the be...
Background In order to clear HCV in chronically infected patients, treatment with combinations of pa...
Hepatitis C virus (HCV) inhibitors include direct-acting antivirals (DAAs) such as NS3 serine protea...
Different HCV subtypes may naturally harbor different resistance selection to anti-NS5a inhibitors. ...
Background: Direct-acting antivirals (DAAs) are predicted to transform hepatitis C therapy, yet litt...
Several new direct-acting antiviral (DAA) drugs are in development for chronic hepatitis C viral (HC...
Treatment with pan-genotypic direct-acting antivirals, targeting different viral proteins, is the be...
Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide a...
BACKGROUND: Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed wheth...
The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients w...